At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DRTS Alpha Tau Medical
Not Yet Opened 11-05 16:00:00 EST
13.30
-0.73
-5.20%
盘后13.30
+0.000.00%
19:58 EST
High14.01Low12.98Vol671.91K
Open13.93D1 Closing14.03Amplitude7.37%
Mkt Cap1.23BTradable Cap848.47MTotal Shares92.33M
T/O8.95MT/O Rate1.05%Tradable Shares63.79M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Alpha Tau Announces Inclusion in the Flagship Ta-90 and Ta-125 Indices of the Tel Aviv Stock Exchange
THOMSON REUTERS  ·  10-30
Alpha Tau Announces Inclusion in the Flagship Ta-90 and Ta-125 Indices of the Tel Aviv Stock Exchange
Alpha Tau and Samsung Medical Center Sign Mou to Explore Clinical Trial of Alpha Dart® for Pancreatic Cancer Patients in Korea
THOMSON REUTERS  ·  10-22
Alpha Tau and Samsung Medical Center Sign Mou to Explore Clinical Trial of Alpha Dart® for Pancreatic Cancer Patients in Korea
27x P B For Alpha Tau Medical (DRTS) Following FDA REGAIN Trial Expansion?
Simply Wall St.  ·  10-21
27x P B For Alpha Tau Medical (DRTS) Following FDA REGAIN Trial Expansion?
Alpha Tau Medical Price Target Maintained with a $16.00/Share by HC Wainwright & Co.
Dow Jones  ·  10-21
Alpha Tau Medical Price Target Maintained with a $16.00/Share by HC Wainwright & Co.
FDA Greenlights Expansion of Alpha Tau’s Brain Cancer Trial, With New Data Weeks Away (NASDAQ: DRTS)
TIPRANKS  ·  10-19
FDA Greenlights Expansion of Alpha Tau’s Brain Cancer Trial, With New Data Weeks Away (NASDAQ: DRTS)
FDA Approves Expansion of Alpha Tau’s Glioblastoma Trial to 20 Patients
Reuters  ·  10-19
FDA Approves Expansion of Alpha Tau’s Glioblastoma Trial to 20 Patients
Alpha Tau Announces FDA Approval to Expand Alpha Dart® U.S. Recurrent Glioblastoma Regain Trial; New Trial Data to be Presented at Sno 2026 Annual Meeting
THOMSON REUTERS  ·  10-19
Alpha Tau Announces FDA Approval to Expand Alpha Dart® U.S. Recurrent Glioblastoma Regain Trial; New Trial Data to be Presented at Sno 2026 Annual Meeting
Alpha Tau Medical Joins Barclays Biotech 1x1 Day Investor Meetings
Reuters  ·  10-05
Alpha Tau Medical Joins Barclays Biotech 1x1 Day Investor Meetings
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Vistra, Nike to Open Higher
MT Newswires Live  ·  10-05
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Vistra, Nike to Open Higher
Alpha Tau Medical is Maintained at Overweight by Barclays
Dow Jones  ·  09-03
Alpha Tau Medical is Maintained at Overweight by Barclays
Alpha Tau price target raised to $30 from $17 at Barclays
TIPRANKS  ·  09-03
Alpha Tau price target raised to $30 from $17 at Barclays
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phreesia (PHR), Alpha Tau (DRTS) and Fortrea Holdings Inc. (FTRE)
TIPRANKS  ·  09-03
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phreesia (PHR), Alpha Tau (DRTS) and Fortrea Holdings Inc. (FTRE)
Alpha Tau CFO Levy to Join H.C. Wainwright Global Investor Conference Fireside Chat
Reuters  ·  09-02
Alpha Tau CFO Levy to Join H.C. Wainwright Global Investor Conference Fireside Chat
Analysts Have Conflicting Sentiments on These Healthcare Companies: PROCEPT BioRobotics (PRCT), Invivyd (IVVD) and Alpha Tau (DRTS)
TIPRANKS  ·  09-01
Analysts Have Conflicting Sentiments on These Healthcare Companies: PROCEPT BioRobotics (PRCT), Invivyd (IVVD) and Alpha Tau (DRTS)
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as US, Iran Exchange Attacks
MT Newswires Live  ·  08-31
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as US, Iran Exchange Attacks
Alpha Tau Completes Enrollment in 48-Patient Impact Pancreatic Cancer Alpha DaRT Pilot Study
Reuters  ·  08-31
Alpha Tau Completes Enrollment in 48-Patient Impact Pancreatic Cancer Alpha DaRT Pilot Study
Alpha Tau Completes Patient Enrollment in Its Multicenter Impact Pancreatic Cancer Pilot Study of Alpha Dart® Following Strong Demand and Multiple Expansions
THOMSON REUTERS  ·  08-31
Alpha Tau Completes Patient Enrollment in Its Multicenter Impact Pancreatic Cancer Pilot Study of Alpha Dart® Following Strong Demand and Multiple Expansions
Top Executive Makes Notable Move in Alpha Tau Medical’s Insider Activity
TIPRANKS  ·  08-26
Top Executive Makes Notable Move in Alpha Tau Medical’s Insider Activity
Alpha Tau Medical CFO Raphi Levy Disposes of $43,058.04 in Common Shares
Reuters  ·  08-25
Alpha Tau Medical CFO Raphi Levy Disposes of $43,058.04 in Common Shares
Nano Dimension Appoints Oramed CEO Nadav Kidron to Board to Chair Strategy, Capital Allocation Committee
Reuters  ·  08-17
Nano Dimension Appoints Oramed CEO Nadav Kidron to Board to Chair Strategy, Capital Allocation Committee
No data available

Introduction

Company Name.
Alpha Tau Medical
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Issue price:
--